{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:29:54Z","timestamp":1787135394123,"version":"build-2736575974"},"reference-count":39,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the efficacy of topical levofloxacin and gatifloxacin at different durations in reducing conjunctival bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In total, 285 patients (290 eyes) scheduled to undergo ophthalmic surgery were divided into 6 groups to receive either gatifloxacin or levofloxacin eye drops for 1 day (12 times\/day), 2 days (6 times\/day), or 3 days (4 times\/day) before surgery. Conjunctival sac specimens were collected from all patients before treatment (T0) and after treatment (T1). All specimens were inoculated onto Columbia blood agar plates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Before treatment, the culture positivity rate was 50.34% for 290 samples, and after treatment, the culture positivity rate was 11.72% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                      <jats:italic toggle=\"yes\">Corynebacterium<\/jats:italic>\n                      spp. and\n                      <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic>\n                      spp. were the most predominantly detected microbial groups before and after treatment. The bacterial eradication rate was higher in the gatifloxacin group (87.01%) than in the levofloxacin group (81.15%). There was no difference in culture positivity between gatifloxacin 1-, 2-, and 3-day groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). The culture positivity rate was significantly higher in the levofloxacin 1-day group than in the 2- and 3-day groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Both drugs were effective in removing gram-positive bacillus at different durations (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), but only the levofloxacin treatment for 3 days significantly reduced the positive cultures of gram-positive cocci in the conjunctival sac (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study demonstrated that preoperative use of levofloxacin to prevent infection takes at least 2\u20133 days, and 1 day is a sufficient duration for topical gatifloxacin to significantly reduce conjunctival bacterial flora.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683251366114","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:53:50Z","timestamp":1759856030000},"page":"598-603","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Topical Gatifloxacin and Levofloxacin at Different Durations in Eliminating Conjunctival Bacterial Flora"],"prefix":"10.1177","volume":"41","author":[{"given":"Junqin","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Chongqing Key Laboratory of Prevention and Treatment of Major Blinding Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chongqing Key Laboratory of Prevention and Treatment of Major Blinding Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chongqing Key Laboratory of Prevention and Treatment of Major Blinding Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dangdang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chongqing Key Laboratory of Prevention and Treatment of Major Blinding Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-7060","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chongqing Key Laboratory of Prevention and Treatment of Major Blinding Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1659-x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00113-16"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32239-5"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-29231-1_15"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2014.06.042"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.06.024"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0088"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.jcrs.0000000000000757"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-023-02816-w"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.06.029"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2013.02.039"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.031"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235662"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(98)00126-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00007"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0146"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.2.383"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2004.01.005"},{"issue":"3","key":"e_1_3_2_21_2","first-page":"207","article-title":"The new fluoroquinolones: A critical review","volume":"10","author":"Zhanel GG","year":"1999","unstructured":"Zhanel GG, , Walkty A, , Vercaigne L, et al. The new fluoroquinolones: A critical review. Can J Infect Dis, 1999; 10(3):207\u2013238.","journal-title":"Can J Infect Dis"},{"issue":"3","key":"e_1_3_2_22_2","article-title":"Moxifloxacin","volume":"57","author":"Balfour JA","year":"1999","unstructured":"Balfour JA, , Wiseman LR. Moxifloxacin. Drugs, 1999; 57(3):363\u2013373, 374.","journal-title":"Drugs"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0091"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2020.01.08"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(86)90477-0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.147"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000437"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102198"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.2.163"},{"key":"e_1_3_2_30_2","first-page":"1","article-title":"ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: Data, dilemmas and conclusions","author":"Barry P","year":"2013","unstructured":"Barry P, , Cordov\u00e9s L, , Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: Data, dilemmas and conclusions. Eur Soc Cataract Refractive Surgeons, 2013:1\u201344.","journal-title":"Eur Soc Cataract Refractive Surgeons"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.03.013"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1199"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/677633"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2007.08.011"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01617-06"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.3.319"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700501"},{"issue":"1","key":"e_1_3_2_38_2","first-page":"40","article-title":"Optimal duration for the use of 0.5% LevofloxacinEye drops before vitreoretinal surgery","volume":"6","author":"Li X","year":"2017","unstructured":"Li X, , Liang X, , Tang L, et al. Optimal duration for the use of 0.5% LevofloxacinEye drops before vitreoretinal surgery. Asia Pac J Ophthalmol (Phila), 2017; 6(1):40\u201344.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-008-0517-y"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.034"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683251366114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251366114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251366114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:09:56Z","timestamp":1787134196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683251366114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.1177\/10807683251366114"],"URL":"https:\/\/doi.org\/10.1177\/10807683251366114","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}